Update shared on18 Sep 2025
Fair value Decreased 5.33%The consensus price target for Olympus has been revised downward, primarily reflecting a modest decrease in both the company’s future P/E ratio and discount rate, resulting in a lower fair value estimate of ¥2006.
What's in the News
- Olympus launched the VISERA S OTV-S500 imaging platform in the U.S., integrating advanced diagnostic features for ENT and urology with enhanced image quality, compatibility, and content management capabilities.
- The company lowered its consolidated FY2026 guidance, with revenue now projected at ¥998,000 million (from ¥999,000 million), operating profit at ¥136,000 million (from ¥150,000 million), and basic EPS at ¥84.62 (from ¥94.44).
- Olympus reported no shares repurchased and no capital deployed under its previously announced buyback program.
- Olympus formed a strategic partnership with Revival Healthcare Capital, co-founding Swan EndoSurgical Inc. and jointly committing up to $458 million to develop an endoluminal robotics platform for GI treatments, with Revival holding majority equity and an Olympus acquisition option.
- Olympus and FluoGuide A/S entered a non-exclusive collaboration to evaluate FG001 for improved tumor imaging in head and neck cancer surgeries, with no initial payment or 2025 financial impact.
Valuation Changes
Summary of Valuation Changes for Olympus
- The Consensus Analyst Price Target has fallen from ¥2119 to ¥2006.
- The Future P/E for Olympus has fallen slightly from 21.39x to 20.66x.
- The Discount Rate for Olympus has fallen slightly from 5.81% to 5.69%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.